鎖住年輕的秘密，其實沒有想象中複雜，甚至可以一步到位！要針對修復老化輪廓，蛻變出緊緻飽滿的面頰、清晰流暢的輪廓綫，就不得不提及榮獲Cosmopolitan Best of the Best PANEL CHOICE 2024 實試美團評鑑大賞 2024 的HArmonyCa™️美神針™️。不但以專利結合兩大醫美元素2，真正做到即時提拉並刺激膠原自生1*†‡，更獲科研實證達98.5%真實用家體驗到緊緻效果3§‖，從內而外透出年輕光華！
登入 瀏覽文章可賺取積分
專利結合兩大元素² 徹底還原緊緻¹
輪廓老化，其實並非表面看上去那麽簡單。其中的原因來自皮膚細胞內的膠原蛋白和彈性纖維分解，及至透明質酸流失，令肌膚組織失去結構、柔軟度和彈性，外表上便出現皺紋、嘴邊贅肉及顯得鬆弛下垂4-6。要修復肌膚狀態，僅憑單一有效成份未必足以針對不同問題。
有別於一般的膠原再生醫美療程，HArmonyCa™️美神針™️同時蘊含透明質酸和CaHA微球兩大醫美元素2，先透過透明質酸的彈性和凝聚力來即時撐起肌膚，一次做到無需等待、即現拉提的效果1*†‡，同時另一成分CaHA激活膠原再生力，深入肌底重建緊密細緻的肌膚結構1*†‡，帶來漸進式逆轉鬆弛下垂的持久改善，讓肌膚更顯緊緻貼面，逐步昇華超乎想像的彈性和豐盈感1*†‡。
無可比擬的專屬膠原自生 自然又放心
效果自然當然最重要！科研證實，與同類型膠原再生產品相比，HArmonyCa™️美神針™️從療程後第一週開始就能更高度滲透入肌膚之內、直接促進新生膠原，並於第2週起展現更顯著及更持久的拉提力7^。另一國際研究亦顯示，HArmonyCa™️美神針™️能在一年間持效漸進的展現提升，讓超過七成半用家在一年後依然對效果感到滿意3§‖。由於其主要成分都能與身體相容、並能被代謝分解8，更獲得歐盟CE的認證9，自然放心又可靠，絕對是你對抗初老最值得的投資！
醫美小貼士 療程前必須注意！
想還原初生緊緻感，療程的第一步，就是選擇最好最可靠的給自己。記住認明醫學美容中心有廠商Allergan Aesthetics每半年頒發的HArmonyCa™️美神針™️原廠供應證書，及產品外盒上貼有防僞鐳射標籤。
想了解更多有關療程的詳細內容及價格，可向 HArmonyCa™️美神針™️ 原廠供應的醫學美容中心 查詢，或緊貼 HArmonyCa™️美神針™️ 香港官網以獲取第一手美顏資訊。
*Results from a prospective and non-randomised interventional study where HArmonyCa™ was injected in the preauricular region of 15 women. The primary endpoint were the volumetric changes at Day 180. Secondary endpoints included changes in facial tension vectors, time to filler tissue integration and safety profile.1 †Ultrasound and elastography examinations were performed using the Samsung HT 30 ultrasound machine and the ElastoScan HS30/XH30 respectively (Samsung Healthcare Global). When compared to baseline, an increase in density, viscoelasticity, and firmness of the tissue was observed at 60 days and then confirmed at 90 days after treatment. At 180 days after treatment an increase in collagen in the treated areas was confirmed.1 ‡Vectra® H2 (Canfield Scientific, Inc.) was used to assess skin lift and tightening by measuring the changes in FTV at 60, 90, and 180 days after treatment. As compared to pre-treatment values, FTV significantly increased at all timepoints with a median (interquartile-range) increased by 2.2 (1.6– 2.2) mm and 2.0 (1.7–2.2) mm in the right and left side, respectively p<0.0001 each, 180 days after treatment.1 § Results from a 1-year, prospective, open-label, post-marketing study where HArmonyCa™ and HArmonyCa™ Lidocaine were injected in the midface of 140 patients with moderate to severe midface volume deficit. The primary endpoint was responder status based on EI-assessed MFVDS at Month 1. Secondary endpoints included responder status based on EI-assessed and participant-assessed GAIS, change from baseline on FACE-Q Satisfaction with Cheeks questionnaire and change from baseline on FACE-Q Satisfaction with Facial Appearance questionnaire. The mITT population was all treated participants with non-missing baseline MFVDS score. At Month 1, the MFVDS responder status (a participant with at least 1-grade improvement on the MFVDS based on the EI’s live assessment of midface volume deficit) was 82.8% (95% CI: 75.7%–88.5%) in the mITT population for both treatment groups combined.3 ‖The EI-assessed GAIS responder rate (improved or much improved) was 98.5% at Month 1, 98.5% at Month 3, 94.7% at Month 6, 87.8% at Month 9 and 75.6% at Month 12. The participant-assessed GAIS responder rate (improved or much improved) was 91.8% at Month 1, 86.4% at Month 3, 81.2% at Month 6, 75.4% at Month 9 and 72.6% at Month 12.3 ^Results from a pre-clinical animal study of HArmonyCa™ with results demonstrated over 12 weeks which showed that HArmonyCa™ led to an instant and sustained lift following injection.7
References: 1. Urdiales-Gálvez F et al. J Cosmet Dermatol. 2023;22(8):2186–2197; 2. Allergan Aesthetics. Data on File. HArmonyCa™ Manufacturing. October 2023. REF-98172; 3. Allergan Aesthetics. Data on File. M21-787 Responder Rates. REF-125579; 4. Kahn DM and Shaw RB. Facial Plast Surg. 2010;26(5):350–55; 5.Swift A et al. Aesthet Surg J. 2021;41(10):1107–19; 6.Coleman SR and Grover R. Aesthet Surg J. 2006;26(1S):S4–9; 7. Allergan Aesthetics. Data on File. HArmonyCa™ Lidocaine ABVRRTI77172. Lift capacity. October 2023. REF-84448; 8. Segal T et al. 2014 – Post marketing study of safety and efficacy of Crystalys, a calcium hydroxyapatite based filler for facial soft tissue augmentation. Available at: https://www.kosmetischemedizin-online.de/uebersichtsarbeit/post-marketingstudie-zur-sicherheit-und-wirksamkeit-von-crystalys-einem-auf-calcium-hydroxyapatit-basierenden-filler-fuer-die-weichteilaugmentation-im-gesicht/. Accessed December 2024; 9. European Commission, HArmonyCa Lidocaine. CE certificate number: 145133-21-05-21, May 2021.
HArmonyCa™ (Calcium hydroxyapatite, hyaluronic acid gel with lidocaine). All adverse events should be reported to MedDeviceComplaintsAPAC@abbvie.com. Suite 2404-08, 24/F, AIA Tower, 183 Electric Road, North Point, Hong Kong. Tel: (852) 2610 2525 © 2025 Allergan Aesthetics. All rights reserved.
HK-HAR-250002 | 08/JAN/25